Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
A Phase 1b Trial to Evaluate Safety of MB097 in Combination with Pembrolizumab in Melanoma Patients
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Microbiotica Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06540391
- Locations
- 🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷CHU de Lille - Hopital Claude Huriez, Lille, France
🇫🇷Centre Leon Berard, Lyon, France
Pulsed Electromagnetic Field Stimulation and Charcot Foot Ulcer
- Conditions
- Charcot Foot Ulcer
- Interventions
- Device: pulsed electromagnetic field therapyDevice: Transcutanous electrical nerve stimulation
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 34
- Registration Number
- NCT06527131
- Locations
- 🇪🇬
Physical Therapy Cairo University, Giza, Egypt
Powdered Intrawound Vancomycin in Open Fractures Trial
- Conditions
- Open FractureInfection, Surgical SiteFractures, BoneTraumaPost-Operative Wound InfectionFractures, OpenWound Infection
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 350
- Registration Number
- NCT06504992
- Locations
- 🇨🇦
Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada
Irrisept Solution for Instrumented Spine Surgery
- Conditions
- Post-Op ComplicationSpine SurgerySite InfectionSurgical Site InfectionSpinal InstrumentationIndex Spinal InstrumentationLayer-by-Layer ClosureLocoregional Flap-Based Closure
- Interventions
- Device: Chlorhexidine gluconate solution
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Rhode Island Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06439953
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
Haemoglobin And Vancomycin Pharmacokinetics in the Cerebrospinal Fluid Following Subarachnoid Haemorrhage
- Conditions
- Subarachnoid Hemorrhage
- Interventions
- Procedure: Insertion of drains
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-04-18
- Target Recruit Count
- 14
- Registration Number
- NCT06373640
Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model
- Conditions
- Severe Infection
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Central South University
- Target Recruit Count
- 112
- Registration Number
- NCT06161870
- Locations
- 🇨🇳
Central South University, Changsha, Hunan, China
Antibiotics and Vaccine Immune Responses Study
- Conditions
- Vaccine Response Impaired
- Interventions
- Biological: BCG vaccineBiological: Yellow Fever vaccine
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-04-04
- Target Recruit Count
- 348
- Registration Number
- NCT06148025
- Locations
- 🇦🇺
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
Infection Prophylaxis in Total Joint Replacement
- Conditions
- Periprosthetic Joint Infection
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 21006
- Registration Number
- NCT06126614
- Locations
- 🇨🇦
Hamilton Health Sciences - Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
- Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 39
- Registration Number
- NCT06126731
- Locations
- 🇨🇭
Oncolgy Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
🇬🇧The Royal Marsden NHS Foundation Trust, London Borough of Sutton, United Kingdom
Infection Rates Between Using of Vancomycin Versus Gentamycin in Primary ACLR
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 110
- Registration Number
- NCT06050785
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.